17:52 , Aug 3, 2018 |  BC Week In Review  |  Company News

Laekna gets rights to Novartis cancer candidates

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) acquired exclusive, worldwide rights to develop and commercialize two clinical stage cancer compounds from Novartis AG (NYSE:NVS; SIX:NOVN). The pharma will take an equity stake in Laekna, which will...
20:26 , Aug 1, 2018 |  BC Extra  |  Company News

Laekna gets rights to Novartis cancer candidates

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) acquired exclusive, worldwide rights to develop and commercialize two clinical stage cancer compounds from Novartis AG (NYSE:NVS; SIX:NOVN). The pharma will take an equity stake in Laekna, which will...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Afuresertib: Phase I/II data

Data from 29 patients with recurrent ovarian cancer in the Phase I portion of an open-label, international Phase I/II trial showed that once-daily oral afuresertib plus paclitaxel and carboplatin led to dose-limiting toxicities (DLTs) of...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Company News

GlaxoSmithKline, Novartis deal

Novartis and GlaxoSmithKline announced multi-billion dollar deals that will see the pharmas sell assets to one another. Novartis will bolster its portfolio of marketed cancer drugs and GSK will bulk up its vaccine business. The...
07:00 , Apr 28, 2014 |  BioCentury  |  Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
00:03 , Apr 23, 2014 |  BC Extra  |  Top Story

Novartis, GSK swapping assets

Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced multi-billion dollar deals that will see the pharmas sell assets to one another. Novartis will bolster its portfolio of marketed cancer drugs and GSK will...